Objective: Neonatal jaundice results from an increased bilirubin production and decreased hepatic bilirubin conjugation and excretion. Severe hyperbilirubinemia is currently treated with phototherapy or exchange transfusion; however, its prevention by inhibiting bilirubin formation is a more logical strategy. Heme oxygenase (HO), with inducible (HO-1) and constitutive (HO-2) isoenzymes, is the rate-limiting enzyme in heme catabolism, producing equimolar amounts of bilirubin and carbon monoxide (CO). Metalloporphyrins (Mps) are heme derivatives that competitively inhibit HO and thereby suppress hyperbilirubinemia. No systematic studies have been reported evaluating whether the HO isoenzymes are inhibited differentially by various Mps. Identification of Mps that selectively inhibit the inducible HO-1 without affecting the 'housekeeping' HO-2 isoenzyme might be desirable in the clinical setting of hemolytic disease, in which the Hmox1 gene is greatly induced. Although bilirubin production is due to the activity of both HO-1 and HO-2, the inhibition of HO-1 with a relative sparing of HO-2 activity might provide the most selective approach for the treatment of hemolytic disease.
Introduction
Neonatal jaundice results from an imbalance between bilirubin production and bilirubin elimination, the latter reflecting mainly a transient impairment of conjugation in the newborn after birth. It is exacerbated in a number of clinical conditions such as prematurity, 1 but the most severe hyperbilirubinemia is usually secondary to hemolytic conditions such as ABO or Rh incompatibilities and glucose-6-phosphate dehydrogenase deficiency. [2] [3] [4] Hemolysis is more often associated with brain injury (kernicterus). 5 Currently, excessive hyperbilirubinemia is being treated with phototherapy 6, 7 and/or exchange transfusion in most serious and acute cases. 8, 9 These procedures, however, only eliminate bilirubin after it has been produced and accumulated in circulation to a level that could portend even higher, more dangerous, levels. A rational and perhaps more desirable approach would be to prevent the formation of excessive bilirubin.
Heme oxygenase (HO) is the rate-limiting enzyme in the catabolism of heme to bilirubin. 10 HO enzyme activity is primarily due to the action of two isoenzymes, HO-1 and HO-2, both of which are isolated and purified. 11 HO-1 has a molecular weight of 32 kDa, is a gene product of a single mRNA and can be induced by a variety of stimuli such as heme itself, heat shock, heavy metals, glutathione depletion, radiation, ischemia, hypoxia and hyperoxia. 12, 13 It is the predominant form in the spleen, the primary organ responsible for the sequestration and degradation of senescent erythrocytes. Because of this role, HO activity in the spleen is higher than in any other tissue and the HO-1 isoenzyme is believed to be greatly upregulated at all times. 14 In conditions in which the splenic HO system is saturated (such as in hemolysis), the excessive heme load is degraded to a greater extent by the hepatic HO system. In contrast, HO-2, which is considered to be the constitutive form, has a molecular weight of 36 kDa, is the product of two or more transcripts, is not induced by the above stress conditions (except by glucocorticoids) and is the predominant form found in the brain. 12, 13, 15 A third isoenzyme, HO-3, has been identified, but its contribution to heme degradation is minimal because of its low level of activity. 16 Nevertheless, it is the combined activity of all HO isoenzymes that contributes to bodily heme catabolism and is measured as HO activity in vitro.
The endoplasmic reticulum-bound HO cleaves and mediates the oxidation of the a-methene bridge of the heme molecule, yielding equimolar amounts of iron, carbon monoxide (CO) and biliverdin. Bilverdin is sub-sequently reduced to yield bilirubin. 10 This stoichiometry, the insolubility of CO in water and the absence of other significant CO-generating reactions allow the use of measurements of CO to serve as indices of bilirubin formation. Because HO is the rate-limiting enzyme in CO and bilirubin production, its inhibition results in decreased CO and bilirubin production rates. In the context of inhibition of heme catabolism, non-metabolized heme is excreted with the bile into the intestine. 17 Natural and synthetic derivatives of heme (iron protoporphyrin) or metalloporphyrins (Mps) have been found to inhibit competitively in vitro and in vivo HO activity. 18 In vivo administration of Mps results in the suppression of plasma bilirubin, 19 total body CO excretion 20 and biliary heme excretion. 17, 21 As a result, these compounds have potential use for the prevention of neonatal jaundice.
A number of these compounds have been studied in vitro and in vivo for efficacy, safety and route of administration. 18, 20, [22] [23] [24] These include the metal-free (Mf) and metal-containing porphyrins with ring modifications to yield deutero-, meso-, proto-and bis-glycol porphyrins ( Figure 1 ). However, no comprehensive or systematic study has yet been reported that examines whether the two major HO isoenzymes are differentially sensitive to inhibition by Mps. A strategic approach to the treatment of neonatal jaundice would be to selectively inhibit HO-1 activity induced by hemolysis in order to prevent excessive bilirubin formation. However, it would be desirable, if not important, to maintain differentially the activity of the 'housekeeping' HO-2 isoenzyme, which may have a role in the production of CO necessary for physiological functioning, 25 and of bilirubin for the maintenance of tissue antioxidant levels. 26, 27 Alternatively, the selective inhibition of HO-2 could allow the study of the function of HO-2, as well as the physiological roles for CO and bilirubin.
Therefore, we determined the I 50 concentrations of 12 Mps and four Mf porphyrins in the in vitro enzyme activity of HO-1, the predominant isoenzyme in rat spleen, and of HO-2, the predominant isoenzyme in rat brain. Data from studies conducted on mice are also provided for comparison of the four most attractive Mps.
Methods

Animals
The study was approved by the Stanford University Department of Comparative Medicine. Animal use and care were in accordance with the guidelines established by Stanford University's Institutional Animal Care and Use Committee. Adult male Wistar rats (Simonsen Laboratories, Gilroy, CA, USA) weighing 253-371 g (316±33, n ¼ 12) and adult FVB mice (Jackson Laboratory, Bar Harbor, ME, USA) weighing 20-25 g (23 ± 1, n ¼ 9) were used as sources of tissue. Food and water were available ad libitum. All animals were killed by decapitation. Spleen and brain were immediately harvested and processed.
Tissue preparation Spleen (serving as the source of HO-1 isoenzyme) and brain (serving as the source of HO-2 isoenzyme) were diced in nine (10% w/w) and four (20% w/w) volumes of iced buffer, respectively, homogenized with an iced Biohomogenizer (Biospec Products, Bartelsville, OK, USA) and then centrifuged for 60 s at 13 000 Â g. The supernatant was decanted and analyzed for HO activity.
Reagents
Buffer was prepared by dissolving 0.1 mole of KH 2 PO 4 KH 2 O in water, titrating the pH to 7.4 with KOH, and adjusting the volume to 1 l. All Mps and Mf porphyrins (Frontier Scientific, Logan, UT, USA) were dissolved with ethanolamine and carefully neutralized with 1-N HCl to a pH of 7.4 under vortex mixing. The concentration was adjusted to 1.2 mM. 18 Concentrations were then varied through appropriate dilutions with buffer. All experiments were conducted under subdued light.
Stock methemalbumin (1.5 mM heme with 0.15 mM bovine serum albumin) solutions were prepared weekly. 28, 29 The working methemalbumin or HO substrate was prepared daily by diluting one volume of the stock heme solution with nine volumes of buffer.
Reduced nicotinamide adenine dinucleotide phosphate (Sigma/Aldrich, St Louis, MO, USA) was dissolved in buffer to 4.5 mM and prepared fresh daily.
A volume of 6 g of sulfosalicylic acid (Sigma/Aldrich) was dissolved in distilled water and the volume adjusted to 10 ml to yield a 60% (w/v) solution.
All solutions were stored at 4 1C in the dark.
HO activity
HO activity was determined essentially as described previously. 28, 29 A volume of 20 ml of tissue supernatant, representing 4-(for brain) or 2-mg (for spleen) fresh weight of tissue, was mixed in 2-ml amber glass vials containing 20 ml of 150 mM methemalbumin and 20 ml of 4.5 mM nicotinamide adenine dinucleotide phosphate for the total reaction vials (control). For the blank reaction vials, the nicotinamide adenine dinucleotide phosphate was replaced with an equal volume of buffer. The vials were sealed with septum caps and placed in a 37 1C water bath for 5 min of temperature equilibration. The vials were then purged with CO-free air and the incubation was continued. After exactly 15.0 min post purging, the reactions were terminated by the addition of 2 ml 60% (w/v) sulfosalicylic acid. 30 To determine the concentration needed to inhibit HO activity by 50% (I 50 ) for each Mp and Mf porphyrin, varying concentrations of each inhibitor were added to additional total reaction vials in minute (p1.0 ml) volumes.
CO determination CO generated into the vial headspace during each reaction was quantitated by gas chromatography with a Reduction Gas Analyzer (Peak Laboratories, LLC, Mountain View, CA, USA). The headspace gas was passed with CO-free carrier air (B55 ml min À1 ) through a stainless steel column (68 Â 0.53 cm i.d.) packed with 13 Â molecular sieve (Alltech Associates, Deerfield, IL, USA) and operated at 140 1C. Analyzer response to CO, which had a retention time of B30 s, was recorded with an integrating recorder (CR-3A, Shimadzu Scientific Instruments, Columbia, MD, USA) by measuring peak area. The gas chromatography was standardized daily with 0-250 ml volumes of 10.8 ml of CO l À1 air (482 nmol CO l
À1
).
Calculations HO activity is defined as the difference in CO production in the total reaction vial (in the presence of nicotinamide adenine dinucleotide phosphate) minus that of the blank reaction vial. HO activity is expressed as mean±s.d. pmol of CO produced per hour per mg fresh weight. Inhibition is defined as the suppression of HO activity due to the presence of Mp or Mf porphyrin.
Percentage of HO activity is defined as the amount of CO formed at each porphyrin concentration divided by the amount of CO formed by the control vial, that is, with no porphyrin added, times 100.
% HO Activity ¼ CO produced at each ½mM CO produced by control Â100
The concentration of each porphyrin needed to inhibit CO production by 50% (the I 50 value) was determined by interpolation. 
Results
For this study, the proto-, deutero-, meso-and bis-glycol porphyrins with zinc, tin and chromium as the central metal atom, and porphyrins without metal, a total of 16 compounds were evaluated at concentrations of 0-48 mM. Each concentration was tested with tissue preparations from three different rats. Figure 2 presents examples of typical dose-response curves for tin protoporphyrin (SnPP), comparing inhibition of HO-1 (spleen) and HO-2 (brain). Mean HO activity levels for control spleen and brain were 553 ± 85 and 85 ± 11 pmol CO hr-1 mg À1 fresh weight (n ¼ 12), respectively. The I 50 value for HO-1 was interpolated to be 0.47 mM in contrast to 0.10 mM for HO-2. Thus, the HO-1 SI is 0.21. Figure 3 , in contrast, illustrates the dose-response curves for the less-potent inhibitor, zinc protoporphyrin (ZnPP). The I 50 values for both isozymes (5.45 and 2.65 mM, for HO-1 and HO-2, respectively) resulted in an HO-1 SI of 0.49.
In Table 1 , the inhibitory potency of each Mp is ranked on the basis of increasing I 50 concentrations for each isoenzyme.
The order for each Mp is nearly identical for both isoenzymes. Inhibition of HO-1 and HO-2 isoenzymes was found to occur most effectively with tin mesoporphyrin. Some cross-over of the potency order of (metallo)porphyrins does, however, occur. The least effective inhibition of both HO-1 and HO-2 isoenzymes was observed with the Mps zinc deuteroporphyrin (5.25 and 2.10 mM, respectively) and ZnPP (5.45 and 2.65 mM, respectively) and the Mf porphyrins (>48 mM). Because there may be species differences in their sensitivity to Mps, we also determined the I 50 value of four Mps in adult FVB mouse spleen and brain tissues. Mean HO activity levels for control spleen and brain were 429 ± 93 and 60 ± 5 pmol CO hr-1 mg À1 fresh weight (n ¼ 9). We found that for tin mesoporphyrin, CrMP, ZnBG and ZnPP the I 50 values for HO-1 were 0.08, 0.05, 0.12 and 6.00 mM, and for HO-2 the values were 0.03, 0.05, 0.08 and 3.45 mM, respectively, compared with those for the rat (Tables 1 and 2) . Table 2 summarizes the I 50 values with respect to the Mp discriminatory potential toward the two isoenzymes. The most striking finding is that, of all the Mps, the HO-1 SI for SnPP is 0.21, and therefore this compound is the most specific in inhibiting HO-2 over HO-1. Interestingly, Mf bis-glycol and Mf mesoporphyrin appeared to favor inhibition of only HO-2 at the concentration range tested. ZnPP and chromium deuteroporphyrin displayed the smallest indices. However, none of the HO-1 SIs are >1.0, indicating that not one of the tested Mps selectively inhibits HO-1 over HO-2.
Discussion
The HO isoenzymes, HO-1 and HO-2, are different gene products having little similarity in amino-acid or nucleotide sequences, amino-acid composition, transcript number or size. They also differ in gene organization and structure as well as in chromosomal localization. The enzymes, however, have similar mechanisms of heme catalysis, substrate specificity and cofactor/coenzyme requirements. The mechanism of action of the isoenzymes arises from the presence of a conserved sequence of 23 amino acids that forms the 'heme pocket', which is the catalytic site of the enzymes. The 'heme pocket' recognizes the porphyrin ring of the Mps, but not the chelated metal. 31 Therefore, various synthetic Mps can bind to prevent access to the pocket by the natural substrate, heme.
On the basis of the inhibitory potency of each Mp for each isoenzyme (Table 1) , even though the isoenzymes differ vastly in molecular and biochemical properties, they appear to respond similarly to inhibition by each Mp. The most striking finding was that, of all the Mps, the HO-1 SI for SnPP was 0.21, and therefore the most specific in inhibiting HO-2 over HO-1. Surprisingly, Mf bis-glycol and Mf mesoporphyrin inhibited only HO-2, suggesting that a central metal is needed for conferring HO-1 inhibitory properties. There also appeared to be no apparent pattern of inhibitory potency based on the central metal and porphyrin ring, which indicates that the whole molecule confers the degree of 'fit' into the heme pocket allowing for its potency for inhibiting HO as well as its selectivity of HO-2 over HO-1. Tin mesoporphyrin and CrMP most potently inhibit both HO isoenzymes, but ZnMP had fairly low potency. ZnPP and CrBG displayed the largest HO-1 SI values (Table 2 ). In addition, none of the HO-1 SI values are >1.0, indicating that no Mp selectively inhibits HO-1 over HO-2. Nevertheless, CrMP appears to have the best HO-1 selectivity of all Mps with an HO-1 SI of 1.0 in mouse tissues. No species-specific sensitivities to Mps were observed between the rat and mouse.
Previous studies conducted by us 32 and our colleagues 33 investigating the efficacy and selectivity of imidazole-dioxolane compounds have found that they are selective in inhibiting HO-1 over HO-2. These non-porphyrin HO inhibitors have comparable inhibitory potencies toward HO-1 as the Mps, ranging from 0.6 to 20 mM for HO-1 and from 16 to >100 mM for HO-2. These compounds also, similar to some Mps, have little effect on nitric oxide synthase or soluble guanylate cyclase. Some dioxolanes have been found to affect nitric oxide synthas and soluble guanylate cyclase as well as cytochrome P450 in rat tissues. 32 We have performed in vivo studies using azalanstat, a dioxolane compound, and found that it can inhibit in vivo HO activity, but only at a high dose (500 mmol kg À1 body weight), and also can induce HO-1. 34 Because these compounds were first designed as inhibitors of cholesterol production by lanosterol 14-a-demethylase, the effects of inhibiting this important pathway may preclude their use in a developing newborn, and as such have been proposed as only pharmacological tools for studying HO-1 and CO. 32, 33 Although major differences exist between HO-1 and HO-2, each isoenzyme is evolutionarily conserved in the primary amino-acid and nucleotide sequences, with homology between HO-1 and HO-2 being B42%. As mentioned above, the Hmox1 gene responds to all types of stimuli, many of which have in common the association with oxidative stress; in contrast, HO-2 is responsive mainly to adrenal glucocorticoids. The consensus sequences necessary for binding several regulatory factors are present and functional in the HO-1 promoter. Only a single glucocorticoid response element is present and functional in the Hmox2 gene. The glucocorticoid response element is not a strong transcriptional promoter, and glucocorticoids exert a prominent regulatory effect on HO-2 expression at the protein level.
Specific activity of HO in different organs varies greatly, the highest HO activity being found in the spleen, testes and the brain. The spleen is the only organ in which, under normal, unstressed conditions, HO-1 is the predominant form. In addition to the function of HO isoenzymes in directly regulating heme and hemoprotein levels, as well as generating CO, HO-2 may have another possible function: that of the 'heme/oxygen sensor' for the cell, with two copies of a sequence 100% identical to the oxygensensing consensus sequence of erythropoietic 5 0 -TTTTGCA-3 0 that is induced by hypoxia. 35, 36 Moreover, in addition to the catalytic heme pocket in the HO-2 isoenzyme, two additional high-affinity heme-binding sites, named heme regulatory motifs, are present, which have conserved cysteine-proline core residues that bind heme with high affinity but are not involved in heme catalysis. These characteristics of the Hmox2 gene, the presence of the consensus sequence of oxygen sensor elements and the highaffinity heme-binding motifs in HO-2 are consistent with its role as a major gene regulator in the cell. 31 Thus, there is good rationale for not perturbing the HO-2 system while trying to control the HO-1 system.
It is intriguing to speculate that, because of these heme regulatory motifs, Mps may also bind to these regions in addition to the heme pocket and thus may explain the greater sensitivity of HO-2 to Mps. Elucidating the contribution of the non-competitive and competitive inhibition of HO-2 to the total inhibitory potency of an Mp is beyond the scope of this paper.
We conclude that SnPP appears to be the most selective Mp in inhibiting HO-2 activity while minimally affecting that of HO-1 in vitro. In general, the HO-2 isoenzyme is more sensitive to inhibition by Mps than is HO-1. The inhibitory potency of each Mp is nearly identical for both isoenzymes. It appears that none of the Mps studied preferentially inhibits HO-1. However, the natural Mp, ZnPP, effectively inhibits HO-1 with a relative sparing of HO-2 activity. In other words, depending on the potency required for clinical efficacy, less-potent Mps, such as ZnPP, would produce a less inhibitory effect on HO-2, while limiting the response of the inducible HO-1, and may be useful as a clinical tool.
